Experimental drug slows progression of early Alzheimer's disease by 60%, study finds. So say the headlines on one of Europe's news sites. It's been mentioned that Eli Lilly's experimental drug #donanemab slowed the progression of Alzheimer's by 60% for patients in the earliest stages of the brain-wasting disease, according to trial data presented at a medical meeting recently. But is all that it seems? Well, there are many different interpretations of this data. See attached letter from the lastest BMJ which suggests much less exciting outcomes and highlights some of the serious side effects. There are people on here with much more expertise on these matters than I but I find it interesting the way this 'silver bullet' is being discussed in the media currently. #alzheimers #useyournoggin #lifestyle #bmj #clinicalstudies #newdrugs
It was all over day time TV but very little said about the side effects. I think it is prudent to ask questions at this stage.
Thank you for sharing this, Mick It's always important to have all the information before touting something as a miracle
Need winning BFCM ads? → Don’t click my profile. ($400M generated with Paid Ads for 150+ DTC brands)
1yHey there Mick! You're spot on about not buying into the hype too soon. Sure, these findings are encouraging but it's just the start of the journey for donanemab. Side effects can't be ignored and we've got to look at the bigger picture here. Let's keep our fingers crossed but also stay grounded in reality.